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DNA vaccination is a promising approach for inducing both humoral and cellular immune responses. For immunotherapy
of HPV-16-associated diseases the E7 protein is considered a prime candidate, as it is expressed in all HPV-16-positive
tumors. Unfortunately, the E7 protein is a very poor inducer of a cytotoxic T-cell response, when being used as antigen in DNA
vaccination. Here we demonstrate that after fusion to protein export/import signals such as the herpes simplex virus ferry
protein VP22, E7 can translocate in vitro from VP22-E7-expressing cells to neighboring cells that do not carry the VP22-E7
gene. In vivo, the VP22-E7 fusion shows significantly increased efficiency in inducing a cytotoxic T-cell response. Our data
suggest that the export function of VP22 plays a major role in this phenomenon, since VP22 can be replaced by classical
protein export signals, without impairing the induction of the E7-specific cellular immune response. However, all E7 fusionINTRODUCTION
The papillomaviruses form a heterogeneous group of
nonenveloped viruses that target the epithelium. The
viruses contain a double stranded circular DNA genome
of approximately 8000 bp. A subgroup of the human
papillomaviruses (HPV) targets the mucosal epithelium
and is considered the causative agent for anogenital
cancer (for review see zur Hausen, 2000). The most
prominent HPV type in this respect is HPV 16, which can
be detected in about half of all invasive cervical cancers
(Bosch et al., 1995; Gissmann, 1992). Worldwide, about
half a million women develop this kind of tumor every
year. Being a major health burden, great efforts are
currently undertaken to develop means for the treatment
and prevention of HPV infections. It is estimated that
within the next 5 years a prophylactic HPV vaccine will
be available, which is based on virus-like particles (Cain
and Howett, 2000; Gissmann et al., 2001; Schiller and
Lowy, 2000). A number of strategies have been pre-
sented for immunotherapy of HPV-associated diseases.
Many of these approaches aim to target the immune
system toward the viral tumor antigen E7 (Bourgault
Villada et al., 2000; Chu et al., 2000; Cornelison, 2000;
Greenstone et al., 1998; He et al., 2000; Liu et al., 2000;
Muderspach et al., 2000; Scha¨fer et al., 1999; Shi et al.,
1999; Tindle, 1997; Wang et al., 2000). In a number of
studies it has been demonstrated that the E7 protein is
1 To whom reprint requests should be addressed at DKFZ-ATV47expressed in all tumor tissues and there are in vitro data
indicating that E7 is required for the growth of tumor cells
(Schwarz et al., 1985; von Knebel Doeberitz et al., 1988).
For these reasons, E7 is considered the prime candidate
to aim for in immunotherapy of cervical cancer and
strategies are under development to disable transform-
ing functions of E7 to assure the safety of genetic vac-
cines using this potential oncogene (Borysiewicz et al.,
1996; Osen et al., 2001). Many different strategies have
been developed to induce a cellular immune response
against tumor antigens. In most instances, these strate-
gies involve either complex viral delivery systems or
rather difficult purification protocols. Both strategies re-
sult in potential vaccines that are either unaffordable to
the general population, in particular in developing coun-
tries, or that raise concerns about safety issues.
In addition to the above discussed strategies, vacci-
nation with naked DNA might be an attractive alternative.
Besides simple production protocols, DNA vaccination
can even be of greater efficiency than other approaches.
In fact, human trials are under way to test DNA vaccines
in the fight against well-known infectious diseases like
HIV, HBV, and malaria (Doolan et al., 1998; Ugen et al.,
1998; Van Herck et al., 1998). Despite its many advan-
tages, the efficiency of antigen delivery remains a major
bottleneck for successful DNA vaccination. Here, we
present evidence that fusion of the HPV 16 E7 to the
herpes simplex virus type 1 VP22 protein and to other
protein export/import signals can improve its ability to
induce a cellular immune response upon DNA vaccina-
tion. The tegument protein VP22 has been identified asconstructs showed significantly elevated protein steady-s
immunogenicity. © 2002 Elsevier Science (USA)
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translocate from HSV-infected cells to uninfected cells
(Elliott and O’Hare, 1997). By fusion of E7 to various
protein export/import signals, we were able to signifi-
cantly improve the weak immunogenicity of the HPV
tumor antigen E7 (Shi et al., 1999; Smahel et al., 1999),
making it a candidate for use in DNA vaccination.
RESULTS
Generation of VP22-E7 fusion constructs
The HPV 16 E7 protein demonstrates only poor immu-
nogenicity if used in DNA vaccination (Shi et al., 1999;
Smahel et al., 1999). It was our hypothesis that fusion of
HSV-1 ferry protein VP22 (Elliott and O’Hare, 1997) to HPV
16 E7 will enable the translocation of E7 protein after
DNA vaccination into different cells, thus enhancing the
induction of a E7-specific cellular immune response. To
test this hypothesis, we generated VP22-E7 fusion genes
by introducing an EcoRV restriction site immediately up-
stream of the VP22 translational stop codon. This site
was used to insert the complete HPV 16 E7 protein or
parts thereof. In addition, we fused E7 to a C-terminal
deletion mutation of VP22. This mutant (VP22C) was
described as deficient in shuttling between cells (Elliott
and O’Hare, 1997). All constructs (for details see Fig. 1
and Material and Methods) were inserted into an expres-
sion vector under the control of the cytomegalovirus
immediate early promoter (pCMV).
Expression of VP22 fusion proteins in vitro, detection
of intercellular transport
To analyze the ability of the different expression con-
structs to express the encoded fusion proteins, the DNAs
were introduced into 293-T cells by a transient transfec-
tion protocol as described under Materials and Methods.
Three days after transfection, cells were harvested and
extracts were analyzed by SDS–PAGE and Western blot-
ting (see Fig. 2). Results indicated correct expression of
the proteins as they migrated to their corresponding size.
Next, we asked whether the VP22 or VP22-E7 proteins
are able to traffic from transfected cells to cocultured
cells that did not receive the genes. We therefore cocul-
tured transfected COS-1 cells with untransfected HeLa
cells at a ratio of 1:6 for 2 days, as previously described
by Elliot and O’Hare (1997). Cells were then fixed and
analyzed by indirect immunofluorescence using VP22-
specific antisera (see Fig. 3). COS-1 cells were distin-
guished from HeLa cells by detection of the SV40 large T
antigen expressed in COS-1 cells. Results of this analy-
sis indicate that VP22 is able to traffic from COS-1 cells
to neighboring HeLa cells as described earlier (Elliott
and O’Hare, 1997). In addition, we observed translocation
of VP22-E7 from COS-1 to HeLa cells, albeit at a lower
efficiency as judged by the fluorescence signal. Also, the
intracellular fluorescence pattern of VP22-E7 differed
very much from the pattern of the unfused VP22. The
VP22-E7 protein tended to aggregate into cytoplasmic
lumps within the transfected COS-1 cells. Similar immu-
nofluorescence patterns were observed when we trans-
fected the constructs into HeLa cells (data not shown).
These observations indicated that E7 reduces VP22-
mediated export by forming intracellular aggregates. In
an attempt to improve translocation of VP22-E7 proteins
we analyzed whether removal of the C-terminal 38 amino
acids of E7 would result in a migration pattern more
similar to that of the unfused VP22 protein. To this end,
we constructed and analyzed another VP22-E7 fusion
gene (VP22-E71–60). The resulting protein showed similar
expression levels when compared to VP22 or VP22-E7
and the intracellular staining pattern of VP22-E71–60 was
indistinguishable from that of the unfused VP22 (see Fig.
3). In addition, VP22-E71–60 translocated more efficiently
from COS-1 cells to HeLa cells, as judged by immuno-
fluorescence microscopy. As expected from previous re-
ports, we were not able to detect protein translocation
when analyzing the C-terminally truncated mutant of
VP22 (VP22C) or the corresponding fusion protein
(VP22C-E7).
FIG. 1. Constructs used for DNA vaccination experiments. The HPV
16 E7 protein or the first 60 amino acids thereof were fused to peptides
enabling cellular protein export (VP22, sec) and/or protein import (VP22,
MTS, TLM). E7 was fused to VP22 via a newly created EcoRV restriction
site, encoding for the additional amino acids aspartate and isoleucine.
These two amino acids flank the E7 portion of the VP22-E71–60 con-
struct. An additional glycine residue is inserted between E7 and MTS
or TLM. For construction of the VP22 deletion mutant the last 34 amino
acids of VP22 were deleted. Note that the published sequence at
position 127 reports a threonine, whereas our constructs as well as the
original construct by Elliott and O’Hare contain a serine (shown in bold)
at this position.
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Fusion to VP22 increases the immunogenicity of HPV
16 E7 in DNA vaccination
Fusion of the HPV E7 protein to VP22 enabled the E7
protein to translocate between cells in vitro. To deter-
mine if fusion to VP22 also influences the ability of E7 to
induce cytotoxic T-cells in vivo, we immunized mice with
the different vector constructs described in Fig. 1. Ten
days after intramuscular injection of 100 g of vector
DNA, mice were sacrificed and the splenocytes pre-
pared as described under Material and Methods. The
splenocytes were restimulated in vitro with irradiated
syngeneic E7-expressing RMA-E7 cells. Five days after
the first restimulation chromium release assays were
performed using either RMA-E7 cells or RMA cells
pulsed with a synthetic peptide representing the E7-
specific CTL epitope E749–57. As negative control, RMA
cells that do not express E7 were used. The results are
shown in Fig. 4 and summarized in Table 1. In none of the
5 mice immunized with the empty vector or the 14 mice
immunized with the pcDNA-E7 construct were we able to
detect the induction of E7-specific cytotoxic T-cells (rep-
resentative results are shown in Fig. 4; one of the 14
pcDNA-E7-immunized mice showed a weak reaction in
the CTL assays, but was scored negative, see Fig. 4*).
This result was not surprising, since it has been reported
previously that the HPV 16 E7 protein demonstrates poor
immunogenicity. In contrast, 4 of 7 of the mice immunized
with the pcDNA VP22-E7 construct developed an E7-
specific cytotoxic immune response as determined by
the ability of the lymphocytes to lyse both E7-expressing
RMA cells and E7-peptide-pulsed RMA cells. As de-
scribed above, the full-length E7 protein seemed to in-
terfere with the shuttling properties of VP22. When we
used the pcDNA VP22-E71–60 construct to immunize mice,
all of the mice were positive for E7-specific CTLs, sug-
gesting that indeed full-length E7 interferes with the
VP22 functions. However, the difference observed for
VP22-E7 and VP22-E71–60 is not statistically significant
and this difference did not reproduce in subsequent
immunization experiments. Surprisingly, the pcDNA
VP22C-E7 construct was also efficient (50% positive
mice) in inducing an immune response when compared
to the pcDNA VP22-E7 construct.
Protein import sequences are not required to boost
the immunogenicity of HPV 16 E7
One explanation for the deletion mutant pcDNA
VP22C increasing the immune response of the E7-
specific DNA vaccine could be a residual functional
activity of this mutant. In fact, protein import but not
export functions have been assigned previously to the
C-terminal portion of VP22. Since no other functional
mutants of VP22 have been described and the mecha-
nisms of the VP22 secretion pathway are poorly under-
stood we decided to separately analyze the influence of
protein export and import in producing an E7-specific
immune response after DNA vaccination. For this, VP22
was replaced by the secretion signal peptide of Ig (see
Fig. 1). In contrast to VP22 the Ig peptide allows protein
export via the classical pathway through the endoplas-
mic reticulum. Similarly, we used the “membrane-trans-
locating sequence” (MTS peptide) of the h region of
Kaposi fibroblast growth factor, which was shown previ-
ously to enable entry of peptides into cells (Rojas et al.).
We then immunized a total of 5 mice with pcDNA secE7-
MTS. Only 1 of the mice developed an E7-specific im-
mune response. In contrast, 6 of 10 mice (in two exper-
iments, see Table 1) immunized with the pcDNA secE7
construct, lacking the MTS signal, produced E7-specific
CTLs. Despite the still relatively small number of mice in
these experimental groups, these results indicate that
import of E7 does not play a role in in vivo immunoge-
nicity. E7-specific Western blot analysis of cells trans-
fected in vitro with the two expression constructs re-
vealed similar levels of protein expression (see Fig. 7).
Similar detrimental effects on the improved immunoge-
nicity of secreted E7 were observed when the MTS
signal was replaced by another protein import signal
(translocation motif; TLM (Oess and Hildt, 2000)). None of
5 mice immunized with an expression vector coding for
FIG. 2. Western blot analysis of VP22 expression. The different VP22
expression constructs were transfected into 293-T cells. VP22 or
VP22-E7 fusion proteins were detected using either a VP22-specific
polyclonal or an E7-specific monoclonal antibody. (Top) Detection of the
VP22 part; (bottom) detection of the E7 part in the fusion proteins.
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secE7-TLM developed detectable amounts of E7-specific
cytotoxic T-cells.
Results from the chromium release assays indicate
that fusion to protein export sequences increases the
immunogenicity of HPV 16 E7. Compared to the E7 gene
alone, all E7 fusion constructs, with the exception of the
two constructs harboring secE7-TLM and secE7-MTS,
showed improved immunogenicity and these differences
FIG. 3. Intercellular transport of VP22 and VP22-E7 fusion proteins detected by indirect immunofluorescence. COS-1 cells were transiently
transfected with expression constructs containing VP22, VP22-E7, VP22-E71–60, VP22C, or VP22C-E7 or the empty vector (-Con). Transfected COS-1
(c) were subsequently cocultured with untransfected HeLa (h) cells for 3 days. VP22 and VP22-E7 fusion proteins were detected using an anti-VP22
polyclonal antiserum (stained with anti-rabbit Cy3 antibodies). COS-1 cells were identified by SV40 T-Ag expression using an anti T-Ag-specific
monoclonal antibody (stained with anti-mouse FITC antibodies).
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were statistically significant. However, the groups of
mice analyzed for the various constructs were too small
to allow direct comparisons between the different E7
fusion constructs. To more clearly demonstrate the ef-
fects on immunogenicity caused by the different E7 fu-
sion partners we tested another 64 mice in two different
experiments. In these experiments we decided to quan-
tify the E7-specific lymphocytes by tetramer staining. In
addition to producing quantitative data, this assay allows
us to measure specific CTLs without prior in vitro re-
stimulation of the lymphocytes. Similarly, we compared
the E7-specific immune response of mice immunized
with expression constructs containing either E7 alone or
E7 fused to protein export signals (secE7 and VP22C-
FIG. 4. Chromium release assays to detect E7-specific cytotoxic T-lymphocytes in immunized mice. Representative results from immunization
experiments using the various expression constructs are shown. For calculation of specific lysis see Material and Methods. *Although we scored all
CTL responses in the group of mice immunized with pcDNA-E7 as negative, 1 of the 14 mice in this group showed a weak reaction against E7. For
the group of mice immunized with secE7-MTS examples of a responder and a nonresponder animal are shown.
51DNA VACCINATION AND HPV 16 E7 PROTEINS
E7) or protein export/import signals (secE7-TLM, VP22-
E7, VP22-E71–60). As in the previous set of experiments
(see Table 1), we were not able to detect E7-specific
lymphocytes in the mice immunized with E7 alone, as
determined by tetramer staining (see Fig. 5). In contrast,
in all groups of mice immunized with expression con-
structs containing an E7 fused to export or export/import
sequences measurable amounts of E7-specific CTLs
were produced. Again, these differences were statistically
significant, when related to the E7 expression construct.
In a subset of the mice analyzed by tetramer staining,
we measured the induction of E7-specific cytotoxic T-
lymphocytes by the chromium release assay (see Table
3). We observed that the data from the chromium release
assays correlated well with the data from the tetramer
staining. This suggests that detection of tetramer-posi-
tive lymphocytes is a good surrogate for the chromium
release assay. In fact, only 1 of 13 mice negative in the
tetramer assay was positive in the CTL assay. Likewise,
there were no mice positive for tetramer staining and
negative in the CTL assay. Two other methods that were
performed for the detection of E7-specific CTLs, the
IFN-ELISPOT-ELISA and the intracellular staining of
IFN in CD8 T-lymphocytes in flow cytometry, also con-
firmed the results obtained by the tetramer assay (data
not shown; Michel et al., manuscript in preparation).
Although in 8 of 10 mice immunized with VP22-E71–60
construct E7-specific lymphocytes could be detected by
tetramer staining, the number of E7-specific lymphocytes
detected in these mice was relatively low (see Fig. 5),
when compared to, e.g., mice immunized with the
VP22-E7 construct. This seems to be in contrast to the
results from the first set of chromium release assays
(see Table 1), where VP22-E71–60-immunized mice
showed strong reactivity against E7. However, in our
assays a frequency of E7-specific T-lymphocytes above
0.4% of all CD8 T-cells (cutoff), as determined by the
tetramer assay, was sufficient to produce potent E7-
specific cell lysis after one round of in vitro restimulation
in a subsequent chromium release assay.
TABLE 1
Induction of E7-Specific CTL Responses in Mice Immunized with E7 Expression Constructs
DNA construct Expt. 1–6 P value
Experiment No.
1 2 3 4 5 6
Empty vector 0/5 n.s. 0/2 0/1 0/2 — — —
E7 0/14 — 0/2 0/1 — 0/1 0/5 0/5
VP22-E7 4/7 0.01 1/2 2/3 1/2 — — —
VP22C-E7 3/6 0.02 — 1/3 2/3 — — —
VP22-E71–60 4/4 0.0005 — — 3/3 1/1 — —
secE7 6/10 0.002 — — — — 3/5 3/5
secE7-MTS 1/5 n.s. — — — — 1/5 —
secE7-TLM 0/5 n.s. — — — — — 0/5
Note. A total of six different experiments were performed using different vector constructs for vaccination of mice. The number of mice scoring
positive (see Material and Methods) in the 51Cr release assays and the total number of animals in each experiment are indicated. Statistical
significance for differences in the number of CTL-positive mice in the various groups in relation to the group of mice immunized with the E7 expression
vector are indicated. n.s., not significant.
FIG. 5. Detection of E7-specific CTL by MHC-I tetramer staining. A
total of 64 mice were immunized with seven different expression
constructs, as shown in Fig. 1. Ten days after DNA vaccination, spleno-
cytes were harvested and E7-specific CTLs were counted among the
CD8 population. (A) Results combined from two different experiments
are shown for each of the 64 mice ({) first set of mice, (E) second set
of mice. (B) Summary of tetramer staining. Numbers indicate positive
mice/total number of mice per group with a tetramer count above cutoff.
aP values are given for the differences in number of CTL-positive mice
in the various groups in comparison with the group of mice immunized
with the E7 expression vector.
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Fusion to secretory signals leads to increased levels
of E7
To shed some further light on the mechanisms that lie
behind the improved immunogenicity of secreted E7, we
performed Western blot analysis to determine the level of
E7 protein produced by the various expression con-
structs. Results indicated that all of the different VP22-E7
fusion proteins as well as the E7 protein fused to export
and/or import signal peptides were expressed to high
levels since they were readily detected by Western blot
using an E7-specific antibody (see Fig. 2). Similarly, the
secE7, secE7-TLM, and secE7-MTS proteins were ex-
pressed at comparable levels (see Fig. 7). In contrast, we
were not able to detect the wild-type E7 (in transiently
transfected cells as well as in the stable RMA-E7 trans-
fectants) in these assays. Failure of detection of E7 was
not unexpected, however, as it was reported previously
that the E7 protein demonstrates a short half-life. To
ascertain that the E7 expression constructs are func-
tional, we performed RT analysis to detect E7-specific
transcripts derived from the constructs pcDNA-E7,
-secE7, -secE7-MTS, -secE7-TLM, -E7-MTS (see Fig. 6).
By this method we were able to detect E7-specific mRNA
for all the constructs analyzed.
The improved immunogenicity of HPV 16 E7 is not
sufficient to break tolerance in E7-transgenic mice
Previously it has been reported that E7-transgenic
mice demonstrate tolerance within the T-cell compart-
ment against the E7-derived CTL epitope E749–57 (Borch-
ers et al., 1999). Under certain circumstances, however,
this tolerance can be broken, e.g., after adoptive transfer
of cells primed ex vivo (Doan et al., 2000). To analyze
whether disruption of tolerance in the transgenic mice
can be achieved, by VP22-mediated in vivo priming, we
immunized transgenic and nontransgenic mice with the
pcDNA VP22-E71–60 construct. While the nontransgenic
mice developed E7-specific CTLs after vaccination with
FIG. 6. Detection of E7-specific transcripts in transiently transfected cells by RT analysis. 293-T cells were transiently transfected with five different
E7 expression constructs. RNA was extracted 48 h posttransfection and RT–PCR was performed using E7-specific oligonucleotides (amplifying 270
bp of the E7 ORF). As positive control, mRNA from Caski cells was used in the RT–PCR (Caski) or DNA of the E7 expression construct was added
to the PCR reaction (pos. control).
FIG. 7. Detection of secE7 proteins in transiently transfected cells by
Western blot analysis. 293-T cells were transfected with the various
expression constructs. E7 proteins were detected in lysates by Western
blot analysis using an E7-specific monoclonal antibody. Note that the
sensitivity of this assay did not allow detection of unfused E7 in
transiently transfected cells or in RMA-E7 cells, although the E7-
specific mRNA was detected in all cells transfected with E7 constructs.
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the VP22-E71–60 construct, this was not the case for the
vaccinated E7-transgenic mice, indicating that despite
its improved immunogenicity in DNA vaccination VP22-
E71–60 is not able to overcome the E7-specific tolerance in
the transgenic animals toward the transgene.
DISCUSSION
The HPV 16 E7 protein is regarded as a prime candi-
date for the development of a therapeutic vaccination
against human papillomavirus-related disease. Unfortu-
nately, the experimental use of HPV 16 E7 in a simple
vaccination with naked plasmid DNA has been proven to
be rather inefficient in inducing a potent CTL response
(Shi et al., 1999; Smahel et al., 1999). Therefore, different
approaches have been undertaken by others to improve
the immunogenicity of E7 in DNA vaccination, among
them mutating the pRb binding pocket (Smahel et al.,
1999), fusion with heat shock protein (Chu et al., 2000)
and directing the protein into lysosomal compartments (Ji
et al., 1999). In this study, we demonstrated that fusion of
protein export signals to the unmodified HPV 16 E7
protein considerably increases the induction of E7-spe-
cific CTL after DNA vaccination.
The work is based on the hypothesis that, after DNA
vaccination, the E7 proteins linked to protein export sig-
nals will be released from the transfected cells, thereby
enabling an efficient transfer of the antigen from nonpro-
fessional to professional antigen presenting cells (cross
priming). Neither direct priming nor cross priming seems
to be an exclusive mechanism for the induction of CTL
responses after DNA vaccination (Whitton et al., 1999).
Therefore, it can be speculated that modified E7 genes
improve immune presentation in different manners, ei-
ther through enhanced direct priming by transfected
APCs or amplified cross-presentation after release from
transfected nonprofessional antigen presenting cells.
The herpes simplex virus tegument protein VP22 was
used in this study to enable intercellular transport of
fused E7 proteins. VP22 has been previously described
as a member of the so-called ferry proteins, as it is able
to traffic from HSV-infected to uninfected cells. The func-
tional significance of the VP22 trafficking functions for
the HSV 1 infection cycle is still undetermined. Likewise,
the mechanisms by which VP22 is able to leave the
infected cells are unknown, although it was suggested
that VP22 follows a nonclassical export pathway (Elliott
and O’Hare, 1997). Despite these open questions about
the role and functions of VP22, it has been demonstrated
that VP22 can be used to deliver proteins such as p53 or
thymidine kinase into cells in vitro where these proteins
exhibit their natural functions (Phelan et al., 1998; Dilber
et al., 1999).
Use of VP22 in DNA immunization has been ad-
dressed by others: Hung et al. showed that VP22, similar
to what is described in this report, boosts immunogenic-
ity of HPV type 16 E7 in a mouse tumor model (Hung et
al., 2001). In another study, Oliveira et al. (2001) demon-
strated increased immunogenicity of a model antigen
(yellow fluorescence protein) after fusion to bovine her-
pes virus VP22.
Our in vitro analysis indicated that the VP22-E7 fusion
proteins are able to translocate between cells. However,
the full-length E7 protein seems to interfere with VP22
functions, while fusion of the first 60 amino acids of E7
resulted in translocation efficiencies indistinguishable
from those seen for unfused VP22. More important, the
VP22-E7 fusions showed drastically improved immuno-
genicity when applied as a DNA vaccine in mice. While
attempts to evoke a CTL response using the E7 gene
alone failed, 37 of 47 mice exposed to any one of the
VP22-E7 constructs (VP22-E7, VP22C-E7, VP22-E71–60)
developed E7-specific CTLs. Positive effects of VP22 in
DNA vaccination have also been observed when a “shuf-
fled” E7 gene was used as antigen (Osen et al., 2001).
The increased immunogenicity is unlikely to be due to an
adjuvant effect by the CpG motifs (Krieg, 1999) present in
the expression constructs. Although the VP22 has a high
G  C content, typical for a HSV1 gene, the actual
frequency of CpG motifs in the VP22-E7 constructs is not
significantly higher compared to the E7 expression vec-
tors (see Table 2). Sequence analysis revealed the pres-
ence of 10 general CpG-S signals within the VP22 gene.
This leads to an increase in the frequency of motifs from
4.75 to 5.58 sites/kbp for pcDNA-E7 and pcDNA-VP22-E7,
respectively. Considering only the optimal CpG-S motifs
(one present in VP22), we found 1.23 sites/kbp in the
pcDNA-E7 construct versus 1.21 sites/kbp in the pcDNA-
VP22-E7 construct.
Surprisingly, a deletion mutant of VP22 demonstrated
effects similar to those of the wild-type protein, suggest-
ing that other mechanisms than intercellular transport
TABLE 2
CpG-S Elements Present in the Expression Constructs
Used for DNA Immunization
Vector construct
CpG-S general CpG-S best
n (sites) Sites/kb n (sites) Sites/kb
pcDNA3.1 E7 27 4.75 7 1.23
pcDNA3.1 VP22 37 5.84 8 1.26
pcDNA3.1 VP22-E7 37 5.58 8 1.21
pcDNA3.1 VP22-E71–60 37 5.68 8 1.23
pcDNA3.1 VP22C-E7 34 5.21 8 1.23
pcDNA3.1 secE7 27 4.67 7 1.21
pcDNA3.1 secE7-MTS 27 4.64 7 1.20
pcDNA3.1 secE7-TLM 27 4.64 7 1.20
VP22 10 11.11 1 0.11
E7 0 — 0 —
Note. Frequency of general CpG-S (R-R-CpG-Y-Y) and optimal CpG-S
(G-A-CpG-T-C/T) elements in the expression vectors (Krieg, 1999).
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play an additional role in the improved immunogenicity of
the fusion proteins. There might be several explanations
for the observed activity of VP22 and the VP22 deletion
mutant to enhance the immunogenicity of E7. First, the
total amount of de novo synthesized E7 might be in-
creased after fusion to VP22 despite the fact that all
constructs used in this study contain the same promoter.
In fact, relatively large quantities of the VP22-E7 fusion
proteins were detected in Western blot analysis of tran-
siently transfected cells in vitro (see Fig. 2). In contrast,
we were not able to detect the unfused E7 protein, even
in the stably transfected RMA-E7 cells. This is consistent
with the reported high turnover rate of the E7 protein.
However, we did not analyze whether the increased E7
steady-state levels observed for all fusions of VP22 and
E7 were due to increased de novo synthesis or to in-
creased protein stability. Regarding steady-state levels
and the immunogenicity of a protein, one has to clearly
distinguish between direct and cross priming as major
mechanisms for the immune presentation of the protein.
While high turnover rates are likely to be favorable for a
potent presentation of epitopes by the cell that ex-
presses the antigen itself (direct priming), an increased
half-life and subsequent accumulation of the protein
within the cell would support the post-apoptotic or post-
necrotic transfer of protein to professional antigen pre-
senting cells. Therefore, increased protein half-life might
be an additional mechanism, besides protein export, for
the enhanced immunogenicity of the fusion proteins. On
the other hand, the steady-state levels of proteins are not
necessarily a good indicator of their immunogenicity. In
fact, it has been demonstrated that decreasing the half-
life of proteins, e.g., by fusion to ubiquitin, can signifi-
cantly improve their ability to induce CTLs, although the
fusion leads to protein levels below the limit of detection
(Rodriguez et al., 1997). A further explanation for the
activity of VP22C-E7 might be the possibility that the
deletion mutant still exhibits protein export activity. This
would be in line with the observations that we made
using another set of E7 expression constructs to immu-
nize mice. When we fused the signal peptide of Ig with
the E7 protein to allow the export of E7 through the
classical pathway involving the endoplasmic reticulum,
we noticed a similar increase in immunogenicity to that
observed for the VP22-E7 or VP22C-E7 fusion genes.
Again, we observed a much increased steady-state level
of E7 after fusion to the Ig signal peptide. Adding a
protein import signal (either the MTS or the TLM) to the
secreted E7 seems rather to interfere with the ability to
evoke E7-specific CTLs; however, this observation is not
statistically significant (total number of CTL-positive mice
for secE7, 14/20; secE7-TLM and secE7-MTS, 8/20, P 
0.11). It is possible that the added MTS signal releases
the E7 protein prematurely from the endoplasmic reticu-
lum and thereby prevents export mediated by the signal
peptide Ig-sec. In comparison to the secE7-MTS (-TLM)
proteins, we did not observe elevated protein levels for
secE7. From these results we hypothesize that the im-
munogenicity of E7 can be boosted by providing means
for protein export. In contrast to our finding, Hung et al.
did not observe increased immunogenicity of E7 when
fused to a similar VP22 truncate, as used in our experi-
ments (Hung et al., 2001). These differences might be
explained by the different vaccination protocols (DNA
injection vs gene gun), but might also be a result of the
rather small number of mice analyzed in the study by
Hung et al.
Besides protein trafficking, the modifications that were
introduced into the E7 protein are likely to affect other
parameters that, as a result, might influence antigenicity.
The rate of protein de novo synthesis and proteolytic
processing might for instance also be contributive to
increased MHC class I presentation. The addition of
protein export signals does not generally lead to an
improved induction of cellular immune responses by
DNA vaccines. Piechocki et al. (2001) analyzed cytoplas-
mic and secreted human ErbB-2 proto-oncogenes in
DNA vaccination. The cytoplasmic ErbB-2 variant was
slightly superior in inducing CTL responses to the se-
creted ErbB-2 variant, which was interpreted as a result
of a TH2-biased immune response induced by the se-
creted ErbB-2 variant. Similarly, You et al. (2001) tested a
secreted versus a cytoplasmic version of the hepatitis B
virus e antigen and found elevated immunogenicity for
the secreted antigen only after additional fusion of an
IgG Fc fragment. It can be hypothesized that secretory
TABLE 3
Detection of E7-Specific CTLs by Tetramer Staining
and Chromium Release Assay
Immunogen
E7-specific CTL after DNA vaccination
Tetramer staininga
(ex vivo)
51Cr release assay
after in vitro restb
Empty 0/2 0/2
E7 0/5 0/5
secE7 4/5 4/5
secE7-TLM 3/6 3/6
VP22-E7 5/5 5/5
VP22-E71–60 3/5* 4/5
VP22C-E7 5/5 5/5
Note. To determine if tetramer assays can be used as a surrogate for
chromium release assays, E7-specific CTLs were measured in a sub-
set of mice by both tetramer staining and chromium release assay.
a Mice with a E7-tetramer-specific count above 0.4% among all CD8
T-cells were scored “tetramer-positive.”
b A CTL response was scored positive when the E7-specific lysis
was at least 15% above that of the negative control (RMA cells without
E7 peptide, at an effector to target ratio of 20:1). Note that with the
exception of one mouse all mice scored identically in both assays. This
one mouse (*) was negative in the E7-specific tetramer assay but
became positive in the chromium release assay after one round of in
vitro restimulation.
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signals are able to improve the immunogenicity of weak
antigens such as the E7 protein, e.g., by directing the
protein out of the cytoplasm, where it might have direct
or indirect modulating activities on the immune presen-
tation by the host cell. Such mechanisms in immune
escape were suggested earlier by Frazer et al. (1999) for
the E7 protein. Thus, rerouting E7 to different compart-
ments (extracellular or lysosomal (Lin et al., 1996) would
allow bypassing limitations in antigen processing and
presentation. Accordingly, strong antigens such as
ErbB-2 (Piechocki et al., 2001), for which such restrictions
do not exist, are not further improved by fusion to protein
export signals.
MATERIAL AND METHODS
Cloning of VP22-E7 fusion constructs
The VP22 (UL49) gene (Elliott and Meredith, 1992;
Knopf and Kaerner, 1980) of HSV-1 was amplified by PCR
with the plasmid pBCHGVP22 (contains VP22 from the
Elliott and O’Hare vector pGE109) as template and the
primers VP22a (5-TTTTGGATCCATGACCTCTCGCCGCT-
CCGTGAAGTCGGGTCCGCGGG-3) and VP22b (5-TTT-
TAAGCTTAGATATCCTCGACGGGCCGTCTGGGGCGAG-
AAGCGGAG-3) for the full-length VP22 gene and the
primers VP22a and VP22c (5-TTTTAAGCTTAGATATC-
GACGTCCTGCACCACGTCTGGATTCAC-3) for the C-ter-
minal truncated VP22C gene. PCR fragments were
cloned into the vector pBlueskript (KSII) via the intro-
duced 5 BamHI and 3 HindIII sites. A full-length HPV 16
E7 gene with a carboxy-terminal translational stop codon
and two flanking EcoRV sites was isolated (Mu¨ller et al.,
1997) and cloned into the introduced EcoRV site of both
the VP22 and VP22C genes. In addition, a truncated
HPV 16 E7 gene encoding the first 60 amino acids of E7
(E71–60) flanked by two EcoRV sites was isolated (Mu¨ller
et al., 1997) and cloned into the EcoRV site of the VP22
gene.
Using the introduced BamHI and HindIII sites the
VP22, VP22C, VP22-E7, VP22C-E7, and VP22-E71–60
genes were further subcloned into the eukaryotic ex-
pression vector pcDNA3.1() (Invitrogen, Groningen).
The constructs were used for gene expression in mam-
malian cells in vitro and in mice in vivo following DNA
vaccination. Sequence analysis revealed three se-
quence variations in the cloned VP22 gene compared to
the VP22 sequence reported previously (Elliott and
O’Hare, 1997), in detail, Met30 3 Ile; Gly95 3 Asp;
Thr1293 Ser. Variation Thr1293 Ser was also found in
the original VP22-encoding vector pGE109 (constructed
by Elliott and O’Hare), whereas this was not the case for
the two other variations. The region of the VP22 gene
carrying the remaining two variations was subsequently
replaced by the original sequence of vector pGE109
using the internal SfiI site of the VP22 sequence and the
BglII site at the 5 end of the VP22 gene in vector pGE109
and the BamHI site at the 5 end of the VP22 gene in the
constructs with VP22, VP22-E7, and VP22-E71–60 as insert.
Cloning of E7, secE7, secE7-MTS, and secE7-TLM
The HPV 16 E7 gene was isolated from the vector
pCEP4 HPV 16 E7 by the 5 KpnI site and the 3 XhoI site
and subcloned into the eukaryotic expression vector
pcDNA3.1() (Invitrogen, Groningen). The correct com-
position of the vector obtained, pcDNA3.1() E7, was
confirmed by sequence analysis. The Ig chain leader
sequence was fused to the 5 end of the E7 gene
(secE7) using PCR with the vector pcDNA3.1() E7 as
template, the two overlapping forward primers secE7-1
and secE7-2, and the reverse primer E7r: secE7-1,
5-TTTTGGATCCACCATGGAGACAGACACACTCCTGCTA-
TGGGTACTGCTGCTCTGGG-3; secE7-2, 5-TACTGCTG-
CTCTGGGTTCCAGGTTCCACTGGTGACATGCATGGAGA-
TACACCTACATTGC-3; E7r, 5-TTTTAAGCTTATGGTTTC-
TGAGAACAGATGGGG-3. The MTS or the TLM was
fused at the 3 end of the E7 gene (E7-MTS or E7-
TLM) by PCR using the vector pcDNA3.1() E7 as
template and the forward primer E7f and reverse
primer E7-MTS, or E7-TLM, respectively. E7f, 5-TTT-
TGGATCCACCATGCATGGAGATACACC-3; E7-MTS,
5-TTTTAAGCTTAGGGTGCGGCAAGAAGAACAGGGAGAA-
GAACGGCTGCCCCGGGTTTCTGAGAACAGATGGGGC-3;
E7-TLM, 5-TTTTAAGCTTAGGGGTCGCCGATG-CGAGA-
GAAGATAGAAGACAGGGGCCCGGGTTTCTGAGAACAG-
ATGGG-3. Using the introduced 5 BamHI site and the 3
HindIII site secE7, E7-MTS and E7-TLM were cloned into
vector pBlueskript (KSII) for sequence analysis and into
vector pcDNA3.1() for eukaryotic gene expression. By
recombining the gene secE7 with the genes E7-MTS or
E7-TLM, using the internal NsiI site of E7 and the 3
HindIII sites of the E7-MTS or the E7-TLM gene, an E7
gene was obtained with a 5 Ig leader sequence
and either a 3 membrane translocating sequence
(secE7-MTS) or a 3 translocation motif (secE7-TLM). For
eukaryotic gene expression secE7-MTS and secE7-TLM
were subcloned into pcDNA3.1().
Purification of plasmid DNA for DNA vaccination
Plasmids used in DNA vaccination were purified from
Escherichia coli DH5 via alkali lysis and CsCl density
gradient centrifugation. The supercoiled plasmid DNA
was resuspended in H2O and stored at20°C until used
in the DNA vaccination experiments.
In vitro analysis of intercellular transport
COS-1 cells were transfected with the different
pcDNA3.1-based VP22 and VP22-E7 expression vectors
using Effectene (Qiagen, Hilden). Transfection was per-
formed as suggested by the manufacturer with 5 g of
plasmid DNA in 100 l of buffer EC, 8 l of Enhancer, and
20 l of Effectene in 6-well plates. Cotransfection with a
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lacZ reporter plasmid revealed a transfection efficacy of
about 20–40% positive cells. Twenty-four hours after
transfection, COS-1 cells were extensively washed with
PBS, trypsinized, and mixed with untreated HeLa cells at
a ratio of COS-1:HeLa 1:6 in DMEM 10% FCS, glutamine,
and antibiotics. These mixed cell suspensions were
grown on cover slides for 48 h and subsequently ana-
lyzed for the distribution of VP22 proteins using indirect
immunofluorescence. Cells were fixed for 5 min with
100% methanol at room temperature and blocked for 10
min with PBS/0.05% Tween/5% FCS. Proteins were de-
tected with the polyclonal rabbit anti-VP22 antibody
SHVP22Rb (Zentgraf, DKFZ) at a dilution of 1:500. To
distinguish between HeLa and COS-1 cells the T-antigen
was codetected with the monoclonal mouse anti-SV40
T-antigen antibody (a kind gift of Dr. Pawlita (MacArthur
and Walter, 1984)) at a dilution of 1:250. Nuclei of cells
were stained with DAPI at a dilution of 1:1000.
Mice
C57BL/6 mice from Charles River WIGA (Sulzfeld, Ger-
many) and transgenic mice expressing the oncogenes
E6 and E7 of HPV 16 under the control of the bovine
keratin VI promoter–enhancer sequence (Borchers et al.,
1999) were kept under conventional conditions and stan-
dard diet at the animal facilities of the DKFZ.
Cell lines and culture conditions
RMA cells (Ljunggren and Ka¨rre, 1985) and RMA-E7
transfectant cells (Speidel et al., 1997) are syngeneic to
C57BL/6 mice and were cultured in RPMI 1640 supple-
mented with 5–10% FCS, 100 U/ml of penicillin, 0.1 mg/ml
of streptomycin, and 4 mM glutamine. Additionally, 0.8
mg/ml of G418 was given to the cultured RMA-E7 cells to
maintain stable expression of the E7 transgene. COS-1,
HeLa, and 293-T cells were grown in DMEM with 10%
FCS, penicillin/streptomycin, and glutamine.
Analysis of eukaryotic protein expression
Twenty-four hours after seeding 1  106 293-T cells in
96-mm dishes, cells were transfected with 5 g of plas-
mid DNA using the Chen–Okayama transfection proto-
col. Cells were supplied with fresh medium 24 h post-
transfection and grown at 37°C and 5% CO2 for a further
72 h. To analyze the transgene expression, transfected
cells were washed with PBS, detached by trypsin diges-
tion, and spun down at 1000 g for 5 min. The cells were
resuspended in 100 l of PBS and stored overnight at
20°C. After addition of 100 l of 2 SDS sample buffer
cells were heated up for 10 min at 95°C, refrozen at
20°C, and again boiled as described before. Proteins
were separated in SDS–PAGE and blotted on nitrocellu-
lose for proteins with VP22 fusion, or PVDF membrane
for proteins without VP22 fusion. The corresponding pro-
teins were detected using enhanced chemilumines-
cence with either the polyclonal rabbit anti-VP22 anti-
serum SHVP22Rb (Zentgraf, DKFZ) or a monoclonal
mouse anti-E7 antibody (Zymed).
RT–PCR
Total RNA of transfected 293-T cells was extracted
with the RNeasy Mini kit (Qiagen, Hilden) according to
the manufacturer’s protocol. Total RNA (1 g) was
treated with DNase I before cDNA synthesis was
achieved with random hexamer primers and the com-
mercially available Omniscript RT Kit (Qiagen, Hilden).
Duplicate reactions either with or without reverse tran-
scriptase were performed for the control of remaining
DNA contamination. One fourth of the reaction volume
was used in PCR using Taq DNA polymerase (Fischer
Biotech) and the following HPV 16 E7-specific primers:
5-ACATTGCATGAATATATGTTAGATTTGCAA-3 and 5-
TCTGAGAACAGATGGGGCAC-3. PCR products were an-
alyzed by agarose gel electrophoresis.
DNA vaccination of mice
Six- to 8-week-old female C57BL/6 mice were treated
by bilateral injection of 50 l of 10 M cardiotoxin into
each tibialis anterior muscle 5 to 6 days prior to DNA
injection. For vaccination, 50 l of plasmid DNA (1 g/l
in PBS) was injected into each pretreated muscle. Ten
days later mice were killed and lymphocytes isolated out
of the spleen.
In vitro restimulation of CTL lines
-Irradiated (100 Gy) RMA-E7 cells (1–2  106) were
added to cultures of 2 107 isolated lymphocytes, which
were pretreated with ACT (17 mM Tris/HCl, 0.16 M NH4Cl,
pH 7.2) to deplete erythrocytes. Cells were grown in 10
ml of MEM (Sigma, Deisenhofen) supplemented with
10% FCS, 105 M -mercaptoethanol, 4 mM glutamine,
100 U/ml of penicillin, and 0.1 mg/ml of streptomycin.
Effector cells were expanded in 2 ml of the above-men-
tioned medium with additional 2.5% supernatant of a
concanavalin-A-induced rat spleen cell culture, 25 mM
methyl--mannopyranosid (Sigma, Deisenhofen), and
1–2  105 -irradiated (100 Gy) RMA-E7 plus 5  106
-irradiated (33 Gy) syngeneic feeder cells. Cultures
were grown at 37°C and 7.5% CO2 in a humidified
incubator.
51Cr release assay
Subconfluent growing RMA and RMA-E7 cells were
trypsinized, washed once in PBS, and resuspended in
serum-free RPMI medium with glutamine and antibiotics
(target cells). Target cells (2 106) were labeled with 100
Ci of Na2
51CrO4 for 60–80 min in a volume of 100–150 l
of the above-mentioned medium at 37°C. By centrifuga-
tion at 200 g for 3 min and resuspending in 10 ml of RPMI
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5% FCS, glutamine, and antibiotics, cells were washed
three times. To pulse RMA cells with peptide, 100 nM
E7-derived antigenic peptide RAHYNIVTF (Feldkamp et
al., 1993) was added to the suspension and incubated at
37°C for 20–30 min.
The target cells were seeded in a 96-well round bot-
tom plates (5  103 cells per well) together with titrated
numbers of effector cells. Maximum release and spon-
taneous release of target cells were determined by the
addition of either 5% Triton X-100 or RPMI medium alone,
respectively. Following a 4.5-h incubation at 37°C, 5%
CO2, the assay plate was centrifuged for 3 min at 200 g
and 50 l of culture supernatant was transferred onto a
solid phase scintillation plate (LumaPlate-96, Packard,
Dreieich) and measured in a microplate scintillation
counter (1450 Microbeta Plus, Wallac, Turku). Specific
lysis was calculated as follows: (experimental 51Cr re-
lease  spontaneous 51Cr release)/(maximum 51Cr re-
lease  spontaneous 51Cr release)  100%. A CTL re-
sponse was scored positive when the E7-specific lysis
was at least 15% above that of the negative control (RMA
cells without E7 peptide; at an effector to target ratio of
20:1).
FACS staining with MHC class I tetramers
HPV 16 E749–57 peptide-loaded H-2
b tetramers conju-
gated with phycoerythrin were kindly provided by Ton
N. M. Schumacher (Netherlands Cancer Institute, Am-
sterdam). Ten days postimmunization, T-cells were iso-
lated from the spleen and depleted from erythrocytes.
T-cells (106) were stained in 96-well plates using 1:15
diluted tetramers together with 1:100 diluted fluorescein
isothiocyanate (FITC) anti-mouse CD8a (clone 53-6.7, BD
Pharmingen) in FACS medium (PBS, pH, 7.5, 3% FCS,
0.02% NaN3). After incubation for 30 min at 4°C, cells
were washed five times with 200 l of FACS medium and
subsequent centrifugation at 1000 g for 2 min. Prior to
FACS analysis, cells were resuspended in 400 l of
FACS medium containing 5 l of 7-aminoactinomycin
(7-AAD; BD Pharmingen). A total of 105 events of lympho-
cytes in the living gate (7-AAD negative) were acquired.
Tetramer-positive and CD8-positive cells are shown as
percentages of total CD8 cells.
Statistical analysis
Statistical analysis was performed using Fisher t test.
A difference was considered significant at P  0.02.
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